Abiopharma

🔍 Cox James S (Executive)

Company: Clearwater Analytics Holdings, Inc. (CWAN)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 13,141 shares of Class A Common Stock at $4.4 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: false | shares_owned_after: 498,560.00 | transaction_form_type: 4
• Acquired 3,792 shares of Class A Common Stock at $4.4 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: false | shares_owned_after: 502,352.00 | transaction_form_type: 4
• Acquired 20,035 shares of Class A Common Stock at $4.4 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: false | shares_owned_after: 522,387.00 | transaction_form_type: 4
• Sold 7,425 shares of Class A Common Stock at $24.0709 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: false | shares_owned_after: 514,962.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,870 shares of Class A Common Stock at $24.0716 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: false | shares_owned_after: 510,092.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 2,387 shares of Class A Common Stock at $24.06 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: false | shares_owned_after: 507,705.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 8,271 shares of Class A Common Stock at $24.0716 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: false | shares_owned_after: 499,434.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 12,610 shares of Class A Common Stock at $24.0709 per share (Direct)
  Date: 2026-04-15 | Code: F | equity_swap_involved: false | shares_owned_after: 486,824.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 1,405 shares of Class A Common Stock at $24.06 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: false | shares_owned_after: 485,419.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,000 shares of Class A Common Stock at $24.0718 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: false | shares_owned_after: 480,419.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 13,141 shares of Stock Option (Right to Buy) at $4.4 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2029-05-20 | equity_swap_involved: false | shares_owned_after: 25,911.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 3,792 shares of Stock Option (Right to Buy) at $4.4 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2029-05-20 | equity_swap_involved: false | shares_owned_after: 22,119.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 20,035 shares of Stock Option (Right to Buy) at $4.4 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2029-05-20 | equity_swap_involved: false | shares_owned_after: 2,084.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.
• F2: This transaction was executed in multiple trades at prices ranging from $24.04 USD to $24.08 USD; the price reported above reflects the weighted average sale price.
• F3: This transaction was executed in multiple trades at prices ranging from $24.04 USD to $24.085 USD; the price reported above reflects the weighted average sale price.
• F4: The sale reported on this Form 4 includes shares withheld to cover tax withholding obligations in connection with the exercise and settlement of stock options. The sale is mandated by the Issuer and does not represent a discretionary transaction by the Reporting Person.
• F5: Vests 297,000 share(s) on 02-Nov-2020, 180,000 share(s) on 21-Jan-2020, 105,750 share(s) on 05-Mar-2021, 105,750 share(s) on 01-Jan-2022, 105,750 share(s) on 01-Jan-2023, 105,750 share(s) on 01-Jan-2024